PropertyValue
?:abstract
  • The coronavirus disease 2019 (COVID-19), an acute respiratory disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been declared as a worldwide public health emergency. Interestingly, severe COVID-19 is characterized by fever, hyperferritinemia, and a hyper-inflammatory process with a massive release of pro-inflammatory cytokines, which may be responsible for the high rate of mortality. These findings may advocate for a similarity between severe COVID-19 and some challenging rheumatic diseases, such as adult onset Still\'s disease, secondary hemophagocytic lymphohistiocytosis, and catastrophic anti-phospholipid syndrome, which have been included in the “hyperferritinemic syndrome” category. Furthermore, as performed in these hyper-inflammatory states, severe COVID-19 may benefit from immunomodulatory therapies.
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2020.01130
?:journal
  • Front_Immunol
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/e0e72f47f5a66583bd94c58e8a48d2f604473a14.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7270352.xml.json
?:pmcid
?:pmid
?:pmid
  • 32574264.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
?:type
?:year
  • 2020-05-28

Metadata

Anon_0  
expand all